Stratatech nabs quarter billion dollar contract for burn treatment product

Stratatech Corp., a Madison-based regenerative medicine company, has been awarded a contract valued at up to $247 million by the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response.

The contract is for the advanced development of the company’s skin replacement product, which acts as a medical countermeasure to treat patients with severe thermal burns.

The planned clinical studies will enable Stratatech to file a Biologics License Application with the FDA for the commercial marketing of its flagship tissue, and confirm efficacy in all key patient populations.

The contract also provides for the procurement of the finished product by the U.S. government so as to establish an inventory of the artificial tissue for use in case of a natural or man-made mass casualty emergency.